XML 40 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814
Statements of Cash Flows - USD ($)
 12 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Cash flows from operating activities    
Net loss $ (7,723,404) $ (5,578,690)
Stock-based compensation expense 1,017,938 499,690
Depreciation and amortization 118,202 97,476
Amortization of prepaid research and development-related party (Note 8) 121,984 35,579
Deferred taxes (23,910) (813,697)
Increase in accounts receivable (157,058)  
Increase in inventory (39,442)  
Decrease (increase) in prepaid expenses, other 150,434 (497,322)
Increase in prepaid research and development-related party (Note 8) (150,000) (465,000)
(Decrease) increase in interest payable to Ampio (46,002) 46,002
Increase in accounts payable 547,314 421,870
Increase in accrued compensation 196,503  
(Decrease) increase in payable to Ampio (561,059) 561,059
(Decrease) increase in deferred revenue (85,714) 191,071
Net cash used in operating activities (6,634,214) (5,501,962)
Cash flows used in investing activities    
Deposits (4,886)  
Purchase of ProstaScint Business (1,000,000)  
Purchase of fixed assets   (9,298)
Net cash used in investing activities (1,004,886) (9,298)
Cash flows from financing activities    
Ampio stock subscription payment 5,000,000  
Proceeds from convertible note from Ampio converted to stock 7,400,000 4,600,000
Luoxis option payout pursuant to the merger (27,476)  
Liabilities paid out pursuant to the merger (20,013)  
Contribution from Ampio   637,210
Net cash provided by financing activities 12,352,511 5,237,210
Net change in cash and cash equivalents 4,713,411 (274,050)
Cash and cash equivalents at beginning of period 2,639,650 2,913,700
Cash and cash equivalents at end of period 7,353,061 2,639,650
Non-cash transactions:    
Ampio stock subscription 5,000,000  
Ampio unpaid debt converted to stock, received prior to 2015 4,600,000  
Contingent consideration related to the ProstaScint purchase $ 664,000  
Issuance of common stock in exchange for Vyrix acquired assets   6,803,356
Related party research and development liability included in prepaid research and development-related party   $ 150,000